Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM

New drugs are needed for the treatment of relapsed acute lymphoblastic leukemia and preclinical evaluation of the MEK inhibitor, selumetinib, has shown that this drug has excellent activity in those leukemias with RAS pathway mutations. The proapoptotic protein, BIM is pivotal in the induction of ce...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Haematologica
Main Authors: Matheson, Elizabeth C., Thomas, Huw, Case, Marian, Blair, Helen, Jackson, Rosanna K., Masic, Dino, Veal, Gareth, Halsey, Chris, Newell, David R., Vormoor, Josef, Irving, Julie A.E.
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2019
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6717586/
https://ncbi.nlm.nih.gov/pubmed/30655370
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2017.185975
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki